Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...

The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R ...

The Connecticut resident said she’s a woman of strong faith who believes in the power of prayer and that’s all that helped to ...

The lenalidomide case Another case before the Competition Commission stems from a complaint that accuses the pharmaceutical company Celgene of overpricing the multiple myeloma medicine lenalidomide.

“At the moment, it's taking four or five weeks to see an oncologist for a patient who's suspected of having cancer,” said ...

The Leukemia & Lymphoma Society (LLS) will present new data from its Beat AML® Master Clinical Trial and Pediatric Acute Leukemia (PedAL) ...

Shares of Legend Biotech Co. (NASDAQ:LEGN – Get Free Report) have earned an average recommendation of “Buy” from the thirteen ...

Ariel Investments, an investment management company, released its “Ariel Global Fund” third-quarter 2024 investor letter. A ...

Throughout 2024, the FDA issued new drug approvals and expanded treatment indications across various rheumatologic diseases.

The FDA has approved a new drug called revumenib that can be taken orally to treat acute leukemia in patients 1 year or older. The drug will be marketed under the brand name Revuforj.

Research analysts at Zacks Research upped their FY2024 earnings per share estimates for Bristol-Myers Squibb in a research ...